IMIDomics expands long-standing partnership with Bristol Myers Squibb to advance immune-mediated inflammatory disease treatment research and development

by CATALONIA.HEALTH

This expanded partnership extends the existing relationship between the two companies, advancing their shared commitment to accelerate research and development aimed at treating IMID patients.

Read more

IMIDomics, a Vall d'Hebron spin-off, raises $16.5 million to develop new drugs against immunomediated inflammatory diseases

by Vall d’Hebron

This investment will allow IMIDomics to accelerate the identification of new therapeutic targets and the development of new drugs for immune-mediated inflammatory diseases (IMID), like rheumatoid arth...

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

New breakthrough in developing more pers...

by Universitat de Barcelona

The results show that adenocarcinoma exhibits much more active and fun...

Photos Stream